



IBA – DATA CONCERNING TRANSPARENCY

Louvain-la-Neuve, Belgium, April 1, 2015 - IBA (Ion Beam Applications SA, EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has received on February 27, 2015 a transparency notification, in accordance with Article 29 §1 al.2 of the Transparency Law (law of May 2, 2007 and Royal Decree of February 14, 2008), the content of which is summarized below.

Belgian Anchorage SCRL sold, since April 24, 2014, 435 000 IBA shares with voting rights (50 000 shares sold on March 26, 2015, 225 000 on March 27, 2015, 75 000 on March 30, 2015 and 85 000 on March 31, 2015). On June 27, 2014, an agreement regarding certification of IBA shares in favour of Belgian Anchorage SCRL and concerning 270 464 shares was terminated.

As a consequence:

- i. the sum of the shareholdings of Belgian Anchorage SCRL, IBA Investments SCRL and IBA SA, affiliated companies, has gone on March 27, 2015, below the 25% threshold; and
- ii. on March 31, 2015, Belgian Anchorage SCRL only held 6 204 668 IBA shares with voting rights.

The situation as at March 31, 2015 is as follows:

ENTITY	24 APRIL 2014 (LAST TRANSPARENCY NOTIFICATION FOR BELGIAN ANCHORAGE)		31 MARCH 2015		VARIATION	
	DENOMINATOR		DENOMINATOR			
	27 667 636		28 653 520			
	Shares with voting rights	%	Shares with voting rights	%	Shares with voting rights	%
Belgian Anchorage SCRL	6 910 132	24.98%	6 204 668	21.65%	705 464	3.32%
IBA Investment SCRL	610 852	2.21%	610 852	2.13%	0	0.08%
IBA SA	75 637	0.27%	75 637	0.26%	0	0.01%
Total	7 596 621	27.46%	6 891 157	24.05%	705 464	3.41%

* * *
*



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For more information, please contact

IBA

Caroline Hardy

Corporate Legal Counsel

+32 10 201 159

caroline.hardy@iba-group.com